STAT

JUNE 11, 2023

The sudden resignation of Francis deSouza as the CEO of Illumina Sunday represents anything but an orderly transition — and it leaves a black mark on both his six-year tenure and his luckless quest to acquire the cancer diagnostics firm Grail. But when the story of deSouza’s time as CEO is taught in management classes, it may be that the discussion should not just be about the decisions he made at the end.

117

117

Pharmacy Times

JUNE 11, 2023

Denise Scarpelli, PharmD, MBA, discussed her presentation at the ASHP 2023 Summer Meeting.

Specialty Pharmacies 139

Specialty Pharmacies 139

STAT

JUNE 11, 2023

Just two weeks after surviving an activist investor’s attempt to oust him from Illumina’s board, company CEO Francis deSouza has resigned his roles at the sequencing behemoth, Illumina said Sunday. deSouza stepped down effectively immediately from the CEO position and from the company’s board. He will remain an adviser through next month.

111

111

European Pharmaceutical Review

JUNE 11, 2023

The US Food and Drug Administration (FDA) has approved commercial production at Bristol Myers Squibb’s newest cell therapy manufacturing facility in Devens, Massachusetts. The 244,000 square foot facility in Devens is BMS’ third commercial cell therapy facility in the US. It is located on the company’s existing Devens site, which has been developing, producing, and testing clinical and commercial medicines for over a decade.

FDA 98

FDA 98

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

JUNE 11, 2023

FRANKFURT — A genetically targeted cancer drug from Kura Oncology has helped put more patients’ advanced leukemias into remission, according to updated results from an ongoing clinical trial presented Sunday. Based on data through April 12, 7 of the 20 patients who received a daily dose of 600 milligrams of the company’s drug saw their cancer go into complete remission, a rate of 35%, according to findings presented here at the European Hematology Association’s annual

103

103

The Checkup by Singlecare

JUNE 11, 2023

Compare cetirizine alternatives | Loratadine | Fexofenadine | Levocetirizine | Diphenhydramine | Allegra-D | Natural alternatives | How to switch meds Cetirizine is a generic over-the-counter (OTC) medication that belongs to a group of medications called antihistamines and is available under the brand-name Zyrtec. Antihistamines like cetirizine can help treat symptoms of hay fever or other upper respiratory allergies.

Dosage 81

Dosage Insurance Immunization 81

Drug Topics

JUNE 11, 2023

At least 6 adalimumab biosimilars are set to launch in July 2023.

98

98

pharmaphorum

JUNE 11, 2023

Novartis builds hefty IgAN pipeline with $3.5bn Chinook buy Phil.

98

98

The Checkup by Singlecare

JUNE 11, 2023

Is phenobarbital covered by insurance? | How much does phenobarbital cost without insurance? | How to get phenobarbital without insurance Phenobarbital is a generic prescription barbiturate used as a sedative or anticonvulsant. Healthcare professionals prescribe phenobarbital as a short-term treatment for insomnia or to control seizures. As an injection, phenobarbital sodium is used as a sedative before and after medical procedures and in people with medical conditions that require sedation or i

Insurance 52

Insurance Insurance Coverage Dosage FDA 52

pharmaphorum

JUNE 11, 2023

CMS extends list of drugs with penalties for price hikes Phil.

98

98

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

The Checkup by Singlecare

JUNE 11, 2023

Compare alprazolam alternatives | Klonopin | Zoloft | Cymbalta | Buspirone | Vistaril | Natural alternatives | How to switch meds For reasons both good and bad, Xanax , the brand name for alprazolam , has been a widely known anxiety medication for many years. A rapid onset of action and effectiveness have brought cheers, but the jeers are every bit as loud based on the potential for sedation, addiction, and withdrawal.

Controlled Substances 52

Controlled Substances Labelling Dosage 52

pharmaphorum

JUNE 11, 2023

Illumina CEO resigns amid investor pressure Phil.

97

97

The Checkup by Singlecare

JUNE 11, 2023

Compare amoxicillin clavulanate alternatives | Amoxicillin | Cefdinir | Zithromax | Vibramycin | Levaquin | Natural alternatives | How to switch meds The usefulness of amoxicillin-clavulanate and its brand-name version, Augmentin , is extensive. From sinusitis and pneumonia to acute diverticulitis and emphysema exacerbations, the antibiotic action of Augmentin can tackle a broad spectrum of bacteria.

Labelling 52

Labelling Dosage Hospitals 52

Med Ed 101

JUNE 11, 2023

I’ve had numerous pharmacy technicians and future pharmacy technicians reach out to me over the years for more content to help them prepare for board exams. I’m happy to support more pharmacy peeps than just pharmacists. The biggest challenge for pharmacy technicians has been the PTCB® (Pharmacy Technician Certification Board) exam. We’ve gone through the content […] The post PTCB Free Practice Test appeared first on Med Ed 101.

PTCB 52

PTCB 52

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

The Checkup by Singlecare

JUNE 11, 2023

Compare tadalafil alternatives | Viagra | Stendra | Staxyn | Caverject | Muse | Natural alternatives | How to switch meds While it may feel like a taboo topic, erectile dysfunction (ED) is a very common men’s health concern in middle-aged and older men; so much so that as many as 30 million men in the United States suffer from the disorder. Erectile dysfunction is a type of sexual dysfunction and may also be called impotence.

Dosage 52

Dosage FDA 52

Drug Store News

JUNE 11, 2023

The Mind Your Meds awareness campaign, targeted at patients and caregivers, shares insights on medication adherence and the pharmacy support systems available to help.

52

52

The Checkup by Singlecare

JUNE 11, 2023

Compare metoprolol succinate alternatives | Bisoprolol | Carvedilol | Lisinopril | Entresto | Valsartan | Natural alternatives | How to switch meds Metoprolol succinate is a generic prescription medication that belongs to a group of drugs called beta blockers and is available under the brand-name Toprol XL. Beta blockers can be used to treat a variety of conditions, including high blood pressure (hypertension) , heart failure, angina (chest pain often associated with coronary artery disease), a

Dosage 52

Dosage People Management Labelling Hospitals 52

PharmaShots

JUNE 11, 2023

Shots: The P-III studies evaluating crovalimab (SC, q4w) vs eculizumab (IV, q2w) in a ratio (1:1) & (2:1) in 89 & 204 patients. In the (COMMODORE 2) study, 79.3% vs 79.0% achieved haemolysis control from 5wk. to 25wk., transfusion avoidance (65.7% vs 68.1%) from baseline to 25wk. Improvement in FACIT-fatigue score from baseline to 25wk. across both arms with greater improvement with crovalimab (adjusted mean change 7.8 vs 5.2), AEs (78% vs 80%), serious inf. (3% vs 7%) with no meningococ

40

40

The FDA Law Blog

JUNE 11, 2023

By Mark A. Tobolowsky & David B. Clissold — In May 2023, CDER and CBER published a draft guidance titled “Pediatric Drug Development: Regulatory Considerations – Complying with the Pediatric Research Equity Act [“PREA”] and Qualifying for Pediatric Exclusivity Under the Best Pharmaceuticals for Children Act [“BPCA”]” (the “Draft Guidance”). This Draft Guidance, in part, replaces a 2005 guidance titled “How to Comply with the Pediatric Research Equity Act.

Labelling 40

Labelling FDA 40